No. The CNTF-derived research compound called P021, which Dissolv labels P21, is different from the cell-cycle protein p21. Similar names can lead to very different papers, product records and conclusions. Before reading a claim about “P21,” identify which molecule the source actually studied.
The distinction is especially important when a search result uses the word peptide loosely. Capitalization alone is not a reliable identification system. A source's full name, structure and methods section provide much stronger clues.
What P021 means in the peptide literature
A 2017 original research paper describes P021 as a modified peptide built from a four-residue region of ciliary neurotrophic factor, or CNTF, with an added adamantylated glycine. The paper writes its notation as Ac-DGGLAG-NH2.
The DGGL core corresponds to aspartic acid, glycine, glycine and leucine. The modified terminal component must remain part of the identity description. Copying the typography into plain text as “DGGLAG” can obscure the modification and invite the wrong interpretation as an ordinary string of amino-acid letters.
When checking a material against that paper, preserve the authors' structural figure and explanation rather than trying to reconstruct the complete chemistry from a short product name. This article identifies the literature compound; it does not authenticate the structure of a particular supplied lot.
What p21 means in cell-cycle biology
The human gene CDKN1A encodes cyclin-dependent kinase inhibitor 1A, commonly called p21 or Cip1. That is a different biological identity from a CNTF-derived synthetic compound.
In Harper and colleagues' 1993 study, the p21 Cdk-interacting protein was investigated as an inhibitor of cyclin-dependent kinases. A later 1995 study examined its selectivity among kinase complexes. Those are protein and cell-cycle experiments. They are not evidence that a product labeled P21 reproduces the protein's activity.
Three clues that resolve the name
- CNTF, P021, or adamantylated glycine: investigate whether the source concerns the modified research compound.
- CDKN1A, Cip1, or cyclin-dependent kinase inhibitor: investigate whether it concerns the cell-cycle protein.
- A fragment or reagent labeled “p21 peptide”: read its actual sequence and purpose. It may refer to a protein fragment rather than P021.
These are screening clues, not substitutes for a complete identity record. If a paper mentions both a compound and a protein marker, record which one was administered or added and which one was measured. A measured change in a protein does not make that protein the material under investigation.
Keep each evidence trail separate
The 2024 P021 study in CDKL5-deficiency models describes the compound in its methods and evaluates cell and mouse models. That supplies a useful example of checking both identity and model before summarizing a paper.
A reasonable reading note would identify P021, name the experimental model, and state which endpoint the authors measured. It should not borrow conclusions from unrelated CDKN1A literature. Nor should it turn a model-specific result into a claim about human cognitive improvement or suitability for self-use.
Search more precisely and save the right record
For the modified compound, try the terms “P021 CNTF” together. For the protein, try “CDKN1A p21.” Compare the abstract with the materials-and-methods section before saving a paper to your reference list.
For a research procurement record, retain the full compound description, the reference paper, the supplier's stated identity and any unresolved structural questions. Keep the lot identifier with the supporting documents. A shared short name is insufficient to conclude that the materials match, and a paper is not a certificate for a commercial batch.
Before selecting this research material
For Dissolv's P21 5mg listing, the key question is whether the full structural specification matches the P021 compound in your reference paper. Ask how the terminal modification is specified, which lot-specific method supports identity, and what the labeled amount measures. Do not accept the shared P21 name as the answer. If supporting records are unavailable, preserve that uncertainty in the procurement review; an attractive catalog image cannot resolve it.
The Dissolv catalog item
The P21 5mg listing describes the CNTF-derived P021 research compound. This article does not offer the CDKN1A protein and does not verify equivalence between a supplied lot and the material used in a published experiment.
Research use only. Not for human or veterinary use. Check material identity and documentation with a qualified reviewer before interpreting experimental suitability.
